Company News: Page (1) of 1 - 02/13/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Cabozantinib shows significant activity in the first line for differentiated thyroid cancer

Initial results of phase II trial show 97 percent of patients experienced tumor shrinkage following kinase inhibitor treatment for metastatic, radioactive iodine-resistant disease (February 13, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:Pro AV,Presentors,Business Issues,Presentation,People,Training,Events,email, Inc.,Medicine,Diet,Disease,Surgery,Cancer,Surgery,Medication,Science,Lifestyle,Medical,Biology,Physics,Cancer,Science,Email,Other,
Related Sites: Digital Producer ,   Presentation Master ,   Oceania ,   DMN Newswire ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: DMN Newsletter ,   CMN Newsletter ,   KNews Newsletter ,   Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- @ Copyright, 2017 Digital Media Online, All Rights Reserved